Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.KineMed has extended its collaboration agreement with Bristol-Myers Squibb targeting Alzheimer's disease and other neurodegenerative conditions.
Subscribe to our email newsletter
KineMed is a biotechnology company specialized in translational and personalized medicine.
As per the agreement, KineMed has given license to its technologies to Bristol-Myers Squibb for identifying and characterizing biomarkers for Alzheimer’s disease in cerebrospinal fluid.
KineMed president and CEO David Fineman said KineMed is enabling research on potential treatments that address the causes, rather than the symptoms, of disease.